BRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Reuters

06 Mar

BRIEF-Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 5 (Reuters) - Aquestive Therapeutics Inc AQST.O:

AQUESTIVE THERAPEUTICS, INC. Q4 ADJUSTED EBITDA USD -11.029 MILLION
AQUESTIVE THERAPEUTICS, INC. Q4 PRETAX PROFIT USD -17.069 MILLION VERSUS. IBES ESTIMATE USD -12.7 MILLION
AQUESTIVE THERAPEUTICS, INC. Q4 INCOME FROM OPERATIONS USD -13.579 MILLION VERSUS. IBES ESTIMATE USD -9.57 MILLION
AQUESTIVE THERAPEUTICS, INC. Q4 NET INCOME USD -17.055 MILLION VERSUS. IBES ESTIMATE USD -12.8 MILLION
AQUESTIVE THERAPEUTICS, INC. Q4 REVENUE USD 11.867 MILLION VERSUS. IBES ESTIMATE USD 13.1 MILLION
: QTRLY LOSS PER SHARE $0.19
OUTLOOK FY TOTAL REVENUE $47MLN TO $56 MILLION
FY2025 REVENUE VIEW $53.0 MILLION -- LSEG IBES DATA

Source text: ID:nGNX86ffCW

Further company coverage: AQST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517927099"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517927099\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517927099?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517927099","market":"nz","top_or_hot":-1,"title":"BRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 ADJUSTED EBITDA USD -11.029 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 PRETAX PROFIT USD -17.069 MILLION VERSUS. IBES ESTIMATE USD -12.7 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 INCOME FROM OPERATIONS USD -13.579 MILLION VERSUS. IBES ESTIMATE USD -9.57 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 NET INCOME USD -17.055 MILLION VERSUS. IBES ESTIMATE USD -12.8 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 REVENUE USD 11.867 MILLION VERSUS. IBES ESTIMATE USD 13.1 MILLION</p></li><li><p>: QTRLY LOSS PER SHARE $0.19</p></li><li><p>OUTLOOK FY TOTAL REVENUE $47MLN TO $56 MILLION</p></li><li><p>FY2025 REVENUE VIEW $53.0 MILLION -- LSEG IBES DATA</p></li></ul><p>Source text: <span>ID:nGNX86ffCW</span></p><p>Further company coverage: <span>AQST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-06 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 ADJUSTED EBITDA USD -11.029 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 PRETAX PROFIT USD -17.069 MILLION VERSUS. IBES ESTIMATE USD -12.7 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 INCOME FROM OPERATIONS USD -13.579 MILLION VERSUS. IBES ESTIMATE USD -9.57 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 NET INCOME USD -17.055 MILLION VERSUS. IBES ESTIMATE USD -12.8 MILLION</p></li><li><p>AQUESTIVE THERAPEUTICS, INC. Q4 REVENUE USD 11.867 MILLION VERSUS. IBES ESTIMATE USD 13.1 MILLION</p></li><li><p>: QTRLY LOSS PER SHARE $0.19</p></li><li><p>OUTLOOK FY TOTAL REVENUE $47MLN TO $56 MILLION</p></li><li><p>FY2025 REVENUE VIEW $53.0 MILLION -- LSEG IBES DATA</p></li></ul><p>Source text: <span>ID:nGNX86ffCW</span></p><p>Further company coverage: <span>AQST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AQST","symbol_name":"Aquestive Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nPLX3B3C7C:1","article_id":"2517927099","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517927099","pubTimestamp":1741213542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5 (Reuters) - Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS, INC. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AQST":"Aquestive Therapeutics Inc.","BK4007":"制药"},"translate_title":"简介-Aquestive Therapeutics报告2024年第四季度和全年财务业绩并提供业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9},"content_text":"BRIEF-Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5 (Reuters) - Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS, INC. Q4 ADJUSTED EBITDA USD -11.029 MILLIONAQUESTIVE THERAPEUTICS, INC. Q4 PRETAX PROFIT USD -17.069 MILLION VERSUS. IBES ESTIMATE USD -12.7 MILLIONAQUESTIVE THERAPEUTICS, INC. Q4 INCOME FROM OPERATIONS USD -13.579 MILLION VERSUS. IBES ESTIMATE USD -9.57 MILLIONAQUESTIVE THERAPEUTICS, INC. Q4 NET INCOME USD -17.055 MILLION VERSUS. IBES ESTIMATE USD -12.8 MILLIONAQUESTIVE THERAPEUTICS, INC. Q4 REVENUE USD 11.867 MILLION VERSUS. IBES ESTIMATE USD 13.1 MILLION: QTRLY LOSS PER SHARE $0.19OUTLOOK FY TOTAL REVENUE $47MLN TO $56 MILLIONFY2025 REVENUE VIEW $53.0 MILLION -- LSEG IBES DATASource text: ID:nGNX86ffCWFurther company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}